This is a snippet of the transcript, sign up to read more.
Initially, the plan was to operate under one Clarivate, selling all solutions across the board, but this was failing. It took me about 90 days to realize the extent of the problem and to understand where we were headed. After this period, I suggested that we needed to segment our offerings into separate life sciences, academia, and so on. I worked with other agencies, including McKinsey, to devise a go-to-market strategy.
This is a snippet of the transcript, sign up to read more.
After a two-week analysis, they agreed with my initial suggestion. They recognized that this is what the market and companies like IQVIA are doing. Given my background, we needed to focus on this approach. You can't expect your account managers to sell seven or eight different offerings. If someone comes from life sciences, they struggle when they have to sell academia and other parts of the business, and vice versa.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.